Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
about
A systematic review of oral fungal infections in patients receiving cancer therapy.Prevalence of invasive fungal disease in hematological patients at a tertiary university hospital in SingaporePosaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysPrimary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Pharmacologic and clinical evaluation of posaconazole.Oral complications in the treatment of cancer patients.Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts.Pharmacotherapy approaches to antifungal prophylaxis.Pharmacoeconomic assessment of therapy for invasive aspergillosis.Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.Oral complications and management strategies for patients undergoing cancer therapy
P2860
Q30431307-62C25737-304D-4CE6-B732-8FFC3BC91923Q33830897-1BCC6211-8C29-476B-95B2-7D560E42884FQ35944724-05BB5722-3E90-4D76-B28A-29D7614ABC9EQ35949528-6894393F-03CF-4CB0-90A3-1B4B72844514Q36406975-9BCB9F4A-3F0A-4B61-B990-4BF52DEDE553Q37445943-21FCA239-D635-486F-B183-9E2A863E3ACCQ37838501-49009588-DF30-40DE-A587-45636A0DB4DFQ37839071-E06D2AFB-5C22-4FE5-8FBF-2AA2AF62498DQ38020238-B2017B0D-CFCC-4FA6-B651-BF77F579D562Q38073334-D6CB7379-A787-4E4D-8399-9DA688BD8B29Q38751500-6B9E7114-F3EC-4C0F-AD09-78668D98FFAFQ40562962-261842CD-A910-4A05-A73B-F21C88A313B5Q41703438-6963B542-A0BD-4781-86BA-AE767222940CQ44636050-CC74D29B-4D50-4DC7-AD6C-D152C99DD41CQ57146399-A7AC3CDE-6FC1-45B4-B852-1C42F393B7FE
P2860
Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Economic evaluation of posacon ...... following haematopoietic SCT.
@en
Economic evaluation of posacon ...... following haematopoietic SCT.
@nl
type
label
Economic evaluation of posacon ...... following haematopoietic SCT.
@en
Economic evaluation of posacon ...... following haematopoietic SCT.
@nl
prefLabel
Economic evaluation of posacon ...... following haematopoietic SCT.
@en
Economic evaluation of posacon ...... following haematopoietic SCT.
@nl
P2093
P2860
P356
P1476
Economic evaluation of posacon ...... following haematopoietic SCT.
@en
P2093
E Carreras
F J Sabater
M A Casado
R de la Cámara
P2860
P2888
P304
P356
10.1038/BMT.2009.272
P407
P577
2009-10-05T00:00:00Z
P5875
P6179
1015238650